Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

Delayed Quote. Delayed  - 09/27 05:30:12 pm
243.5 CHF   +0.58%
09/26 HERE’S A : ACIU)’s Alzheimer’s Candidate, Crenezu..
09/25 CURIS : Aurigene to Invest in Curis at Premium Through Waiver of Cer..
09/23 GLOBAL BLOOD GL : Roche, Lifescan, Bayer, Abbott, ARKRAY, I-SENS, Om..
News SummaryMost relevantAll newsSector news 

FDA Approves Breast-Cancer Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
02/22/2013 | 06:05pm CEST

--Drug packs Roche's Herceptin with chemotherapy agent

--Drug approved for use as a first-line, or initial treatment for advanced breast cancer

WASHINGTON--The U.S. Food and Drug Administration Friday approved a powerful new type of drug that will be marketed by Roche Holding AG (ROG.VX, RHHBY) to treat breast cancer.

The drug called, Kadcyla, combines Roche's existing cancer drug, Herceptin, with a powerful chemotherapy agent, and is meant to treat certain types of breast cancer that have spread to other parts of the body.

Herceptin targets a protein called HER2 found on tumors in about 20% to 25% of breast-cancer patients. The two other components of Kadcyla, both developed by ImmunoGen Inc. (>> ImmunoGen, Inc.), are a chemotherapy agent called emtansine that is too potent to be delivered as a conventional medicine, and a linker that connects the two drugs. Herceptin then delivers the package to the tumor cell, where it releases the toxic cargo to kill the cancer.

The FDA's approval of Kadcyla, which was previously known as T-DM1, triggers a $10.5 million payment to ImmunoGen by Roche. ImmunoGen will also receive royalties on sales of up to 5%.

Analysts said the approval was broader than expected. The drug can be marketed for initial treatment rather than just in patients who've tried other therapies, creating a "significantly larger patient population," said Simos Simeondis, an analyst at Cowen and Company.

Roche's Genentech unit said Kadcyla will be available to patients in about two weeks. The drug will be priced at $9,800 a month. The company said there will be a patient-assistance program to help pay for the product.

Agents like Kadcyla are called antibody-drug conjugates and they are the focus of intense interest in the pharmaceutical industry. Roche's Genentech unit has 25 such agents under development for different cancers, including eight in human studies.

The first such agent to gain FDA approval was Seattle Genetics Inc.'s (>> Seattle Genetics, Inc.) Adcetris, for Hodgkin's Lymphoma and another rare cancer. That company and ImmunoGen are each collaborating with big pharmaceutical firms including Bayer AG (BAYRY, BAYN.XE), Eli Lilly & Co. (>> Eli Lilly & Co.), GlaxoSmith Kline PLC (GSK, GSK.LN), Pfizer Inc. (>> Pfizer Inc.), Sanofi (>> Sanofi SA) to develop several types of new cancer drugs.

The approval of Kadcyla was based on a study of about 1,000 women with HER2-positive breast cancer who had been treated previously with Herceptin and a traditional chemotherapy drug. About half of the women were then treated with T-DM1 and the other half were treated with a combination of Xeloda, another Roche drug, and GlaxoSmithKline's Tykerb. The study showed women receiving Kadcyla lived for an average of 31 months, which was about six months longer than women being treated with Xeloda and Tykerb.

However, like other cancer drugs Kadcyla has the potential to cause serious and life-threatening side effects from liver damage or heart problems. The drug can also cause severe birth defects so doctors need to make sure women of child-bearing age aren't pregnant before administering the product.

--Joseph Walker contributed to this story.

Write to Jennifer Corbett Dooren at jennifer.corbett@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING LTD.
09/26 HERE’S A LOOK AT AC IMMUNE LTD : ACIU)’s Alzheimer’s Candidate..
09/25 CURIS : Aurigene to Invest in Curis at Premium Through Waiver of Certain Milesto..
09/25 ROCHE : MILITARY $99,980 Federal Contract Awarded to Roche Diagnostics
09/23 GLOBAL BLOOD GLUCOSE TEST STRIPS MAR : Roche, Lifescan, Bayer, Abbott, ARKRAY, I..
09/23 MEDICINES : HHS forges strategic partnerships with two global companies to devel..
09/23 MEDICINES : and Roche get BARDA awards to develop new antibiotics
09/23 ROCHE : Presolicitation Notice - Maintenance for the Roche Cedex Analyzer
09/22 ROCHE : $5.5 million to help nutley with roche transition
09/22 Epizyme Establishes Collaboration with Foundation Medicine to Support Tazemet..
09/22 ROCHE : Invitation to Roche's Third Quarter Sales 2016 Conference Call
More news
Sector news : Pharmaceuticals - NEC
08:49aDJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJPfizer Throws Out Plan to Split Into Two Companies
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/26 Array Plays Catch-Up In Braf-Mek Derby
09/26 Array Bio's encorafenib-binimetinib combo successful in late-stage melanoma s..
09/25 WEEK IN REVIEW : Jacobson Pharma Raises $85 Million In Hong Kong IPO
09/23 Priority Review Vouchers Revisited
09/23 Bubble Stocks Top The Takeover Premium Charts
Financials ( CHF)
Sales 2016 51 213 M
EBIT 2016 17 978 M
Net income 2016 11 293 M
Debt 2016 10 952 M
Yield 2016 3,53%
P/E ratio 2016 18,16
P/E ratio 2017 16,27
EV / Sales 2016 4,29x
EV / Sales 2017 3,97x
Capitalization 208 694 M
More Financials
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 297  CHF
Spread / Average Target 23%
Consensus details
EPS Revisions
More Estimates Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Daniel O'Day COO-Roche Pharmaceuticals Division
Roland Diggelmann COO-Roche Diagnostics Division
Alan Hippe Chief Financial & Information Technology Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-11.18%215 081
JOHNSON & JOHNSON14.66%322 232
NOVARTIS AG-8.70%211 231
PFIZER INC.4.21%204 049
MERCK & CO., INC.17.66%171 858
More Results